KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accumulated Expenses (2016 - 2025)

Pacira BioSciences has reported Accumulated Expenses over the past 16 years, most recently at $95.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $95.6 million for Q4 2025, up 19.32% from a year ago — trailing twelve months through Dec 2025 was $95.6 million (up 19.32% YoY), and the annual figure for FY2025 was $95.6 million, up 19.32%.
  • Accumulated Expenses for Q4 2025 was $95.6 million at Pacira BioSciences, up from $79.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PCRX hit a ceiling of $127.6 million in Q4 2021 and a floor of $50.2 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $73.7 million (2022), compared with a mean of $73.4 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 79.72% in 2021 and later dropped 29.7% in 2023.
  • Pacira BioSciences' Accumulated Expenses stood at $127.6 million in 2021, then fell by 29.61% to $89.8 million in 2022, then dropped by 28.45% to $64.2 million in 2023, then rose by 24.72% to $80.1 million in 2024, then grew by 19.32% to $95.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $95.6 million (Q4 2025), $79.6 million (Q3 2025), and $71.0 million (Q2 2025) per Business Quant data.